Diagnósticos da América S.A (SA:DASA3) — Market Cap & Net Worth
Market Cap & Net Worth: Diagnósticos da América S.A (DASA3)
Diagnósticos da América S.A (SA:DASA3) has a market capitalization of $696.45 Million (R$3.55 Billion) as of September 20, 2026. Listed on the SA stock exchange, this Brazil-based company holds position #10688 globally and #109 in its home market, demonstrating a 2.53% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Diagnósticos da América S.A's stock price R$2.84 by its total outstanding shares 1249774542 (1.25 Billion). Also see Diagnósticos da América S.A (DASA3) total assets for a full breakdown of the balance sheet.
Diagnósticos da América S.A Market Cap History: 2015 to 2026
Diagnósticos da América S.A's market capitalization history from 2015 to 2026. Data shows change from $2.32 Billion to $696.45 Million (-9.51% CAGR). Also see DASA3 operating cash flow for how efficiently the company converts equity into cash flow.
Index Memberships
Diagnósticos da América S.A is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
SAO PAULO SE IGCX INDEX
IGCX
|
$624.97 Billion | 0.11% | #67 of 155 |
Weight: Diagnósticos da América S.A's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Diagnósticos da América S.A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Diagnósticos da América S.A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Diagnósticos da América S.A stock quote for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.03x
Diagnósticos da América S.A's market cap is 0.03 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $2.32 Billion | $2.79 Billion | $23.81 Million | 0.83x | 97.38x |
| 2016 | $4.07 Billion | $3.04 Billion | $94.74 Million | 1.34x | 42.99x |
| 2017 | $6.35 Billion | $3.40 Billion | $131.44 Million | 1.87x | 48.34x |
| 2018 | $6.30 Billion | $3.93 Billion | $184.38 Million | 1.60x | 34.17x |
| 2019 | $13.88 Billion | $4.36 Billion | $124.78 Million | 3.18x | 111.22x |
| 2020 | $17.43 Billion | $7.04 Billion | -$150.80 Million | 2.48x | N/A |
| 2021 | $8.22 Billion | $10.42 Billion | -$226.57 Million | 0.79x | N/A |
| 2022 | $3.37 Billion | $13.13 Billion | -$386.92 Million | 0.26x | N/A |
| 2023 | $2.36 Billion | $14.25 Billion | -$1.17 Billion | 0.17x | N/A |
| 2024 | $465.93 Million | $15.32 Billion | -$1.20 Billion | 0.03x | N/A |
Competitor Companies of DASA3 by Market Capitalization
Companies near Diagnósticos da América S.A in the global market cap rankings as of September 20, 2026. Review Diagnósticos da América S.A (DASA3) tangible net worth to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Diagnósticos da América S.A by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #89 globally with a market cap of $224.59 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #161 globally with a market cap of $149.61 Billion USD.
- WuXi AppTec Co Ltd (SHG:603259): Ranked #475 globally with a market cap of $57.91 Billion USD ( CN¥395.72 Billion CNY).
- Natera Inc (NASDAQ:NTRA): Ranked #577 globally with a market cap of $47.01 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #89 | Thermo Fisher Scientific Inc | NYSE:TMO | $224.59 Billion | $651.45 |
| #161 | Danaher Corporation | NYSE:DHR | $149.61 Billion | $211.81 |
| #475 | WuXi AppTec Co Ltd | SHG:603259 | $57.91 Billion | CN¥160.00 |
| #577 | Natera Inc | NASDAQ:NTRA | $47.01 Billion | $369.39 |
Diagnósticos da América S.A Historical Marketcap From 2015 to 2026
Between 2015 and today, Diagnósticos da América S.A's market cap moved from $2.32 Billion to $ 696.45 Million, with a yearly change of -9.51%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | R$696.45 Million | -37.44% |
| 2025 | R$1.11 Billion | +138.95% |
| 2024 | R$465.93 Million | -80.25% |
| 2023 | R$2.36 Billion | -29.93% |
| 2022 | R$3.37 Billion | -59.02% |
| 2021 | R$8.22 Billion | -52.87% |
| 2020 | R$17.43 Billion | +25.63% |
| 2019 | R$13.88 Billion | +120.26% |
| 2018 | R$6.30 Billion | -0.84% |
| 2017 | R$6.35 Billion | +56.02% |
| 2016 | R$4.07 Billion | +75.63% |
| 2015 | R$2.32 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of Diagnósticos da América S.A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $696.45 Million USD |
| MoneyControl | $696.45 Million USD |
| MarketWatch | $696.45 Million USD |
| marketcap.company | $696.45 Million USD |
| Reuters | $696.45 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Diagnósticos da América S.A
Diagnósticos da América S.A., together with its subsidiaries, provides diagnostic and hospital services in Brazil and Argentina. It operates through Hospitals and Oncology; Diagnostics and Care Coordination; and International Diagnostics segments. The company offers outpatient doctors; medical and outpatient services; diagnostic support assistants for private patients or partner companies; care c… Read more